Scoping review of rational polytherapy in patients with drug‐resistant epilepsy
Open Access
- 20 December 2022
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (1) , 53-84
Abstract
There is a paucity of literature regarding the optimal selection of combination antiseizure medications (ASMs) for drug‐resistant epilepsy (DRE). The aim of this scoping review is to evaluate current evidence related to “rational polytherapy” among adults with DRE. Using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses for Scoping Reviews (PRISMA‐SCr) guidelines, PubMed, ProQuest, CINAHL, and Cochrane databases were searched using DRE‐ and polytherapy‐related keywords. The exclusion criteria applied included: non‐English; non‐human studies; non‐research studies; participants less than 18 years; status epilepticus; ASM monotherapy; and certain ASMs. In Covidence, two researchers independently reviewed articles for inclusion at each phase, with a third resolving conflicts. Data were extracted, with quality appraisal using the Mixed Methods Appraisal Tool (MMAT). Of the 6477 studies imported for screening, 33 studies were included. Clinical, humanistic, and economic outcomes were reported by 26, 12, and one study, respectively. Common efficacy‐related clinical outcomes included ≥50% reduction in seizure frequency (n = 14), seizure freedom (n = 14), and percent reduction in seizure frequency (n = 8). Common humanistic outcomes included quality of life (n = 4), medication adherence (n = 2), sleep‐related outcomes (n = 2), and physician and patient global assessments (n = 2). The economic study reported quality‐adjusted life years. The median MMAT score was 80 (range: 60–100). Two studies referenced the standard definition of DRE, whereas five studies did not specifically define DRE. Gaps in the literature include limited generalizability, minimal reports in pregnancy, and lack of optimal ASM combinations, among others. Strengths of the evidence include addressing a variety of outcomes. Inconsistent definitions of DRE, small sample sizes, and heterogeneity among studies limit the ability to draw meaningful conclusions. Optimal combinations of ASMs for rational polytherapy for DRE is unclear.Keywords
This publication has 50 references indexed in Scilit:
- Epilepsy Is a Risk Factor for Sudden Cardiac Arrest in the General PopulationPLOS ONE, 2012
- Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVAEpilepsy & Behavior, 2012
- Transient improvement after brief antiepileptic drug withdrawal in the epilepsy monitoring unit—possible relationship to AED toleranceEpilepsia, 2010
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007
- Randomized, Controlled Clinical Trial of Zonisamide as Adjunctive Treatment for Refractory Partial SeizuresEpilepsia, 2004
- Direct Cost of Medical Management of Epilepsy among Adults in Italy: A Prospective Cost‐of‐Illness Study (EPICOS)Epilepsia, 2004
- Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial SeizuresEpilepsia, 2000
- Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinicJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Lamotrigine substitution study: evidence for synergism with sodium valproate?Epilepsy Research, 1997
- High doses of carbamazepine for refractory partial epilepsyArquivos de Neuro-Psiquiatria, 1996